Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15349297 | 0.85 | F2RL3 (0.41) | F2RL3LMNAHRH3 | |
| SCHEMBL5724298 | 0.83 | HRH3 (0.31) | HRH3 | |
| SCHEMBL5723956 | 0.82 | HRH3 (0.33) | F2RL3HRH3 | |
| SCHEMBL15349279 | 0.80 | LMNA (0.56) | LMNAMAPT | |
| SCHEMBL5724279 | 0.75 | HRH3 (0.43) | HRH3OGAMAPT | |
| SCHEMBL5723999 | 0.75 | OGA (0.35) | LMNAOGAMAPT | |
| SCHEMBL5724487 | 0.74 | OGA (0.38) | HRH3OGAMAPT | |
| SCHEMBL5724490 | 0.74 | OGA (0.35) | LMNAOGAMAPT | |
| SCHEMBL5723814 | 0.73 | OGA (0.39) | HRH3OGA | |
| SCHEMBL5723810 | 0.73 | OGA (0.39) | HRH3OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1289498-C | 1-methylcarbapenem derivatives | SANKYO CO (JP) | 2006-12-13 | — | — | CN | disclosed |
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| CN-1486317-A | 1-methylcarbapenem derivatives | ������������ʽ���� | 2004-03-31 | — | — | CN | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | F2RL3 3892/4885LMNA 3159/4885HRH3 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.